Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 12 Most Profitable NASDAQ Stocks to Buy Right Now. On January 27, Truist Securities lifted its price target on the stock to $145 from $140, while maintaining a Buy rating.

According to Tipranks, Truist told investors in a research note that it was revising estimates for YEZTUGO, a prescription drug to lower HIV-1 risk, heading into fourth-quarter earnings. The firm is also adjusting certain timelines following recent updates on upcoming launches, including BIC/LEN and Hepcludex in the United States.

On the same day, Citigroup also provided an update on Gilead Sciences, Inc. (NASDAQ:GILD). The firm lifted its price target on the stock to $156 from $140, while keeping a Buy rating.

Citi’s adjustment came as part of the firm’s broader Q4 preview of biopharmaceutical stocks. The bank expects achievable estimates and reduced policy risk to create a promising environment for the group this year.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company engaged in the development of medicines to prevent and treat various life-threatening diseases, including HIV, viral hepatitis, and cancer.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Defense Stocks to Buy in the S&P 500 and 14 Best Booming Stocks to Buy Right Now.

Disclosure: None.